每年研究成果
每年研究成果
個人檔案
研究專長
藥事經濟學
藥物流行病學
健康經濟學
菸害防制
教育/學術資格
PhD, 醫療服務與政策, University of California, Berkeley
指紋
查看啟用 Yi-Wen Tsai 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 1 類似的個人檔案
過去五年中的合作和熱門研究領域
國家/地區層面的近期外部共同作業。按一下圓點深入探索詳細資料，或
-
Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan
Chen, K. A., Huang, W. M., Chen, E. Y. T., Ho, P. K., Chueh, C. H., Wen, Y. W., Chen, M. H., Chiang, N. J. & Tsai, Y. W., 12月 2024, 於: BMC Cancer. 24, 1, 622.研究成果: Article › 同行評審
開啟存取 -
The 2017 Women’s Health Initiative study and use of hormone therapy: an emulated repeated cross-sectional study
Chueh, C. H., Ho, P. K., Li, W. H., Shiu, M. N., Wang, I. T., Wen, Y. W. & Tsai, Y. W., 12月 2024, 於: BMC Public Health. 24, 1, 1674.研究成果: Article › 同行評審
開啟存取 -
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy
Chueh, C. H., Tsai, Y.-W., Chen, Z. R., Shiu, M. N., Wen, Y. W. & Chiang, N. J., 3月 2023, 於: PharmacoEconomics. p. 307-319研究成果: Article › 同行評審
2 引文 斯高帕斯（Scopus） -
Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma
Tseng, C. Y., Tsai, Y.-W. & Shiu, M. N., 8 11月 2023, 於: Frontiers in Oncology. 13, 1264417.研究成果: Article › 同行評審
開啟存取2 引文 斯高帕斯（Scopus） -
Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration
Chen, Z.-R., Chueh, C.-H., Chiang, N.-J. & Tsai, Y.-W., 11 9月 2023, 於: Cost Effectiveness and Resource Allocation. 21, 1研究成果: Article › 同行評審
1 引文 斯高帕斯（Scopus）